XNAS
EOLS
Market cap513mUSD
Oct 08, Last price
7.80USD
1D
0.78%
1Q
18.00%
IPO
-33.10%
Name
Evolus Inc
Chart & performance
P/E
—
P/S
1.73
EPS
—
Div yield, %
—
Shrs. gr., 5y
13.83%
Rev. gr., 5y
39.36%
Revenues
297m
+11.61%
Net income
-52m
L+2.42%
CFO
-42m
L+134.82%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Evolus, Inc. functions as a performance beauty specialist, supplying medical aesthetic solutions to healthcare practitioners and their patients across the United States. Central to its offerings is Jeuveau, an exclusive formulation of 900 kilodalton purified botulinum toxin type A. This product is specifically engineered to offer a temporary improvement in the appearance of moderate to severe frown lines in adults. The firm was established in 2012 and maintains its primary office in Newport Beach, California.
Key people
Vikram Malik
Chairman of the Board · since 2018
President, Chief Executive Officer, Director · since 2018
Chief Financial Officer, Executive Vice President - Corporate Development · since 2018
Michael M. Jafar
Chief Marketing Officer · since 2018
Simone Blank
Director · since 2018
Independent Director · since 2019
Robert Hayman
Independent Director · since 2018
Independent Director · since 2019
Legal address
c/o REGISTERED AGENT SOLUTIONS, INC., 838 WALKER ROAD SUITE 21-2
Dover, DE 19904
US
Dover, DE 19904
US
Headquarters
520 Newport Center Drive; Suite 1200
Newport Beach, CA 92660
US
Newport Beach, CA 92660
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||